Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.
According to Zacks, “Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company’s principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York. “
A number of other equities analysts have also issued reports on ATNM. B. Riley set a $3.00 target price on shares of Actinium Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, March 14th. Maxim Group set a $3.00 target price on shares of Actinium Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, March 28th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $3.70.
Shares of Actinium Pharmaceuticals traded down $0.05, reaching $0.58, on Tuesday, Marketbeat.com reports. The stock had a trading volume of 3,297,987 shares, compared to its average volume of 1,010,593. Actinium Pharmaceuticals has a fifty-two week low of $0.33 and a fifty-two week high of $1.33.
A number of hedge funds have recently made changes to their positions in ATNM. Anson Funds Management LP bought a new position in Actinium Pharmaceuticals during the first quarter worth $1,502,000. Sabby Management LLC bought a new position in Actinium Pharmaceuticals during the first quarter worth $729,000. Sio Capital Management LLC bought a new stake in Actinium Pharmaceuticals in the 1st quarter valued at $393,000. Worth Venture Partners LLC bought a new stake in Actinium Pharmaceuticals in the 1st quarter valued at $140,000. Finally, D.A. Davidson & CO. increased its holdings in Actinium Pharmaceuticals by 227.1% in the 4th quarter. D.A. Davidson & CO. now owns 157,000 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 109,000 shares during the period.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.